Frontiers in Biomedical Research
As Israel’s popular conference Biomed 2010 begins, we take a look at the biggest developments in Israel’s biotech industry over the last year.
Biopharmaceutical firm NasVax is making waves with its VaxiSome delivery system which helps boost the body’s response to a vaccine.
Israel’s Biomed 2010 hosts top personnel from Roche, JP Morgan Chase and Johnson & Johnson, at an annual event where multi-million dollar pharmaceutical deals are made.
An Israeli discovery allowing stem cells to be cultivated in quantities ample enough to meet the world’s needs means that stem cell therapy could soon be within the reach of millions.
It started life when the founder identified an unmet need in diagnostics. Now Israeli life science company Novamed is planning a spending spree – to buy up American companies and technologies.
A few months ago Israeli drug discovery company Compugen was in deep financial trouble. Now it’s staged a turnaround, attracting interest from international pharmaceutical giant, Pfizer.
A new imaging device from Israel can capture a still image of a beating heart, providing early diagnosis of the world’s Number One killer disease.
Israeli company Itamar Medical has developed a device that can measure the health of your heart from a fingertip test. Now the device has received a seal of approval from the Mayo Clinic.
Prescription drugs mixed inadvertently with over the counter medications can be a lethal cocktail hospitalizing hundreds of thousands of people every year. Now an Israel company has the solution.
As the World Health Organization declares swine flu a pandemic, an Israeli company has begun clinical trials of a universal flu vaccine that could protect against almost every type of flu virus.
Ongoing research at an Israeli university may lead to vaccines that can teach our immune systems to better fight Alzheimer’s disease.
Israel could become a leader in the $3 billion chronic wound industry with a new device that heals wounds faster and more cheaply than alternatives.
A new protein injection developed by Israeli researchers can trigger the regrowth of blood vessels around the heart, offering a potential alternative to risky bypass surgery.
An Israeli biotech company is developing a new peptide that could be used to treat sepsis and septic shock by preventing a cascade of toxic super-antigens in the body.
At Israeli company Biokine Therapeutics, the focus from day one has been on finding drugs to fight cancer. Nine years on, the company believes it’s nearing its goal with a promising potential drug that can be adapted to treat a variety of different cancers, from leukemia, to myeloma, as well as inflammatory diseases.